Abstract
IntroductionIt has been anecdotally observed that ABO blood type may have an impact on the severity of the side-effects experienced by those receiving mRNA vaccination for COVID-19. MethodsAs part of a larger study, a retrospective cross-sectional survey was made available to approximately 33,000 front-line healthcare workers, students and volunteers who were offered voluntary vaccination in a state-wide healthcare system during phase one of the state’s vaccine roll-out. A secondary endpoint of the survey was to determine if there was any relationship between vaccination reactogenicity and ABO blood type. Results4009 responses were received - a 12.15% response rate. 3700 respondents answered the blood type question, and of those, 2878 knew their blood type. By Kruskal-Wallis test, there was no statistically significant association between any blood type and any side effect for either of the COVID-19 mRNA vaccines. ConclusionsCOVID-19 mRNA vaccination may cause significant reactogenicity. However, ABO blood type does not appear to be a predictor of vaccine reactogenicity.
Highlights
It has been anecdotally observed that ABO blood type may have an impact on the severity of the side-effects experienced by those receiving Messenger RNA (mRNA) vaccination for COVID-19
ABO blood type does not appear to be a predictor of vaccine reactogenicity
Messenger RNA vaccines for COVID-19 were introduced rapidly due in large part to existing research by National Institutes of Health staff at the Vaccine Research Center and the preparation of “prototype coronavirus vaccines” to a generic coronavirus [5]
Summary
As part of a larger project evaluating COVID-19 vaccination and work-related absences, this project aimed to further elucidate this relationship beyond the initial anecdotal observations in a population of front-line healthcare workers employed by or working at a large, multi-site, state-wide, tertiary medical system who were offered the mRNA vaccination as part of the phase one vaccine roll-out
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
